Cannon Connect

Exclusive: Houston entrepreneurial hub launches 'future-proofed' online platform

The Cannon launched Cannon Connect — an online platform that takes its community of entrepreneurs, investors, and more online — amid the pandemic and plans for growth. Photo courtesy of The Cannon

When the team at The Cannon — a Houston coworking company with three locations across town — was planning an online platform that would connect members across their properties in January, they didn't see a global pandemic enroute to upend how Houstonians work. It did, however, make the need for an online platform all the more relevant.

Now, Cannon Connect has launched to its members — and it comes equipped with virtual networking, job hunting, resources, and more. The whole goal of the platform is to democratize the programming, resources, and culture The Cannon has created.

"Our recognition was that we have a lot of value we can deliver," says Jon Lambert, CEO of The Cannon. "We want to provide the value that we have to entrepreneurs anywhere and everywhere — we don't want to preclude entrepreneurs, investors, advisers, and service providers from being part of what The Cannon is trying to build just because you're not close to one of our facilities."

Cannon Connect acts as a virtual hub for networking, resources, and more. Photo courtesy of The Cannon

A pivot toward a virtual platform isn't a novel idea, Lambert admits, and other Houston organizations have rolled out their platforms — like Houston Exponential's HTX TechList and Sesh Coworking's Inner Circle. However, The Cannon's main goal is replicating the community it has in its locations and creating an online space for that.

"Having a portal is one thing — creating an environment and an experience where people want to spend their time is another," Lambert says, comparing Cannon Connect to social media platforms and how people use them regularly to stay connected to what's going on.

Another differentiating factor is The Cannon is planning to have its platform used by more than just the Houston ecosystem. Lambert says that over the past year, he's talked to around 30 cities from around the world who are interested in The Cannon's concept. The "future-proofed" virtual platform will enable connectivity and consistency as the company grows.

Current members have access to the portal, and new members can opt in for $30 a month. Image courtesy of The Cannon

"If we're really going to create and grow this community, there's not a building that's big enough for every entrepreneur out there, but certainly in a digital environment, we have the ability to pull those folks in," Lambert tells InnovationMap.

While the conversations on physical spaces in these cities has stalled, Lambert says entering into new markets with a digital-first plan has become the new priority.

The online community is made up of a forum section, jobs board, knowledge center, and more. In the future, The Cannon, which recently acquired Houston crowdfunding platform LetsLaunch, will add in a crowdfunding capability to the site. Live streaming events is another tool that's in the works.

Cannon Connect is available to all Cannon coworking members, and online-only registration is $30 a month or $300 a year. The Cannon team is also working on creating a student membership option, which should be available in the near future.

Learn more in The Cannon's promotional video below:

The Cannon is an Entrepreneurial Ecosystemwww.youtube.com

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted